Literature DB >> 29096785

U=U taking off in 2017.

.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 29096785     DOI： 10.1016/S2352-3018(17)30183-2

Source DB:  PubMed          Journal:  Lancet HIV        ISSN： 2352-3018            Impact factor:   12.767


× No keyword cloud information.
  64 in total

1.  Human Immunodeficiency Virus Transmission Risk in Analytical Treatment Interruption Studies: Relational Factors and Moral Responsibility.

Authors:  Liza Dawson
Journal:  J Infect Dis       Date:  2019-07-02       Impact factor: 5.226

2.  Transmission Risk Among Youth Living With HIV in the U.S.

Authors:  Jacob J van den Berg; Kristi E Gamarel; Andrew O Westfall; J Dennis Fortenberry; Sybil G Hosek; Craig M Wilson; Michelle A Lally
Journal:  J Adolesc Health       Date:  2020-03-10       Impact factor: 5.012

3.  A Systematic Review and Meta-Analysis of Combination Behavioral Interventions Co-Targeting Psychosocial Syndemics and HIV-Related Health Behaviors for Sexual Minority Men.

Authors:  David W Pantalone; Kimberly M Nelson; Abigail W Batchelder; Christopher Chiu; Hamish A Gunn; Keith J Horvath
Journal:  J Sex Res       Date:  2020-02-20

4.  Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy.

Authors:  Jason Gillman; Patrick Janulis; Roy Gulick; Carole L Wallis; Baiba Berzins; Roger Bedimo; Kimberly Smith; Michael Aboud; Babafemi Taiwo
Journal:  J Antimicrob Chemother       Date:  2019-08-01       Impact factor: 5.790

5.  Undetectable = Untransmittable and Your Health: The Personal Benefits of Early and Continuous Therapy for HIV Infection.

Authors:  Mark J Siedner; Virginia Triant
Journal:  J Infect Dis       Date:  2019-01-07       Impact factor: 5.226

6.  Impact of mail order pharmacy use and travel time to pharmacy on viral suppression among people living with HIV.

Authors:  Jessica P Ridgway; Eleanor E Friedman; Justine Choe; Cynthia T Nguyen; Todd Schuble; Natasha N Pettit
Journal:  AIDS Care       Date:  2020-05-04

7.  Cost-effectiveness of preexposure prophylaxis for HIV prevention for conception in the United States.

Authors:  Ashley A Leech; James F Burgess; Meg Sullivan; Wendy Kuohung; Michal Horný; Mari-Lynn Drainoni; Cindy L Christiansen; Benjamin P Linas
Journal:  AIDS       Date:  2018-11-28       Impact factor: 4.177

8.  Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV.

Authors:  Mary Morrow; Samantha MaWhinney; Ryan P Coyle; Stacey S Coleman; Edward M Gardner; Jia-Hua Zheng; Lucas Ellison; Lane R Bushman; Jennifer J Kiser; Peter L Anderson; Jose R Castillo-Mancilla
Journal:  J Infect Dis       Date:  2019-07-19       Impact factor: 5.226

9.  Simulating the End of AIDS in New York: Using Participatory Dynamic Modeling to Improve Implementation of the Ending the Epidemic Initiative.

Authors:  Erika G Martin; Roderick H MacDonald; Daniel E Gordon; Carol-Ann Swain; Travis O'Donnell; John Helmeset; Adenantera Dwicaksono; James M Tesoriero
Journal:  Public Health Rep       Date:  2020 Jul/Aug       Impact factor: 2.792

10.  Predictors of PrEP Uptake Among Patients with Equivalent Access.

Authors:  Sarit A Golub; Rachel A Fikslin; Matthew H Goldberg; Stephanie M Peña; Asa Radix
Journal:  AIDS Behav       Date:  2019-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.